Head to Head Analysis: Trulieve Cannabis (TRLV) and Its Competitors

Trulieve Cannabis (NYSE:TRLV) is one of 898 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Trulieve Cannabis to similar businesses based on the strength of its dividends, institutional ownership, risk, profitability, valuation, earnings and analyst recommendations.

Profitability

This table compares Trulieve Cannabis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.55%	-4.24%	-1.72%
Trulieve Cannabis Competitors	-2,378.15%	-221.75%	-16.00%

Valuation and Earnings

This table compares Trulieve Cannabis and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Trulieve Cannabis	$1.18 billion	-$116.38 million	93.80
Trulieve Cannabis Competitors	$3.65 billion	$3.21 billion	549.32

Trulieve Cannabis’ peers have higher revenue and earnings than Trulieve Cannabis. Trulieve Cannabis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for Trulieve Cannabis and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1	1	1	0	2.00
Trulieve Cannabis Competitors	7740	13788	25594	1021	2.41

Trulieve Cannabis currently has a consensus target price of $15.00, indicating a potential upside of 45.38%. As a group, “Pharmaceuticals” companies have a potential upside of 34.71%. Given Trulieve Cannabis’ higher probable upside, research analysts clearly believe Trulieve Cannabis is more favorable than its peers.

Insider & Institutional Ownership

32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Trulieve Cannabis peers beat Trulieve Cannabis on 7 of the 11 factors compared.

About Trulieve Cannabis

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.